Corcept Therapeutics (CORT) News Today → Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad) Free CORT Stock Alerts $28.09 +0.55 (+2.00%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 4:36 AM | marketbeat.comVictory Capital Management Inc. Sells 32,358 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)Victory Capital Management Inc. reduced its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 40.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,731 shareMay 18 at 2:49 AM | americanbankingnews.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Forecasted to Post Q2 2024 Earnings of $0.20 Per ShareMay 17 at 10:02 PM | marketbeat.comShort Interest in Corcept Therapeutics Incorporated (NASDAQ:CORT) Declines By 6.3%Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) was the target of a significant decrease in short interest in April. As of April 30th, there was short interest totalling 19,800,000 shares, a decrease of 6.3% from the April 15th total of 21,120,000 shares. Currently, 22.1% of the company's stock are sold short. Based on an average daily volume of 1,100,000 shares, the days-to-cover ratio is presently 18.0 days.May 17 at 7:50 AM | marketbeat.comCorcept Therapeutics Incorporated to Post Q2 2024 Earnings of $0.20 Per Share, Zacks Research Forecasts (NASDAQ:CORT)Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Equities researchers at Zacks Research boosted their Q2 2024 earnings estimates for shares of Corcept Therapeutics in a note issued to investors on Thursday, May 16th. Zacks Research analyst K. Das now anticipates that the biotechnolMay 17 at 5:14 AM | americanbankingnews.comSean Maduck Sells 50,000 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) StockMay 16, 2024 | insidertrades.comInsider Selling: Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells 50,000 Shares of StockMay 16, 2024 | marketbeat.comJump Financial LLC Buys Shares of 49,226 Corcept Therapeutics Incorporated (NASDAQ:CORT)Jump Financial LLC bought a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 49,226 shares of the biotechnology company's stock, valued at approximatMay 14, 2024 | americanbankingnews.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Insider Joseph Douglas Lyon Sells 7,227 SharesMay 14, 2024 | insidertrades.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $187,902.00 in StockMay 13, 2024 | finance.yahoo.com3 High Insider Ownership US Growth Companies With Earnings Growth Up To 70%May 8, 2024 | marketbeat.comNew York State Common Retirement Fund Has $2.28 Million Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT)New York State Common Retirement Fund trimmed its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 34.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 70,235 shares of the biotechnology compMay 7, 2024 | insidertrades.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $281,580.00 in StockMay 6, 2024 | marketbeat.comInsider Selling: Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells 10,830 Shares of StockCorcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) insider Joseph Douglas Lyon sold 10,830 shares of the stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $26.00, for a total value of $281,580.00. Following the completion of the sale, the insider now directly owns 7,314 shares of the company's stock, valued at approximately $190,164. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.May 3, 2024 | marketbeat.comCorcept Therapeutics (NASDAQ:CORT) Shares Down 4.5% Corcept Therapeutics (NASDAQ:CORT) Shares Down 4.5%May 3, 2024 | finance.yahoo.comCorcept Therapeutics First Quarter 2024 Earnings: Beats ExpectationsMay 3, 2024 | marketbeat.comQ2 2024 EPS Estimates for Corcept Therapeutics Incorporated (NASDAQ:CORT) Lifted by AnalystCorcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Investment analysts at HC Wainwright increased their Q2 2024 EPS estimates for shares of Corcept Therapeutics in a report released on Thursday, May 2nd. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology companyMay 2, 2024 | marketbeat.comCorcept Therapeutics (NASDAQ:CORT) Price Target Raised to $40.00HC Wainwright lifted their price objective on shares of Corcept Therapeutics from $38.00 to $40.00 and gave the stock a "buy" rating in a research report on Thursday.May 2, 2024 | marketbeat.comCorcept Therapeutics (NASDAQ:CORT) Issues Earnings ResultsCorcept Therapeutics (NASDAQ:CORT - Get Free Report) issued its quarterly earnings results on Wednesday. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.04. Corcept Therapeutics had a net margin of 21.86% and a return on equity of 21.98%. The company had revenue of $146.80 million during the quarter, compared to analyst estimates of $141.19 million. During the same quarter last year, the business posted $0.14 EPS. Corcept Therapeutics's quarterly revenue was up 38.9% compared to the same quarter last year.May 2, 2024 | marketbeat.comCorcept Therapeutics (NASDAQ:CORT) Shares Gap Up on Strong EarningsCorcept Therapeutics (NASDAQ:CORT) Shares Gap Up After Earnings BeatMay 2, 2024 | gurufocus.comQ1 2024 Corcept Therapeutics Inc Earnings Call TranscriptMay 1, 2024 | investorplace.comCORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q1 2024May 1, 2024 | sfgate.comCorcept: Q1 Earnings SnapshotMay 1, 2024 | finance.yahoo.comCorcept Therapeutics Inc (CORT) Outperforms Analyst Estimates in Q1 2024May 1, 2024 | globenewswire.comCorcept Therapeutics Announces First Quarter Financial Results and Provides Corporate UpdateApril 30, 2024 | marketbeat.comJackson Creek Investment Advisors LLC Invests $1.11 Million in Corcept Therapeutics Incorporated (NASDAQ:CORT)Jackson Creek Investment Advisors LLC bought a new position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 34,163 shares of the biotechnology company's stock, valuedApril 29, 2024 | finance.yahoo.comCorcept Completes Enrollment in Phase 4 CATALYST TrialApril 25, 2024 | marketbeat.comCorcept Therapeutics (CORT) Scheduled to Post Earnings on WednesdayCorcept Therapeutics (NASDAQ:CORT) will be releasing earnings after the market closes on Wednesday, May 1, Zacks reports.April 24, 2024 | marketbeat.comCorcept Therapeutics (NASDAQ:CORT) Stock Price Down 3.3%Corcept Therapeutics (NASDAQ:CORT) Trading Down 3.3%April 24, 2024 | globenewswire.comCorcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference CallApril 23, 2024 | markets.businessinsider.comPromising Clinical Outcomes and Market Potential: Buy Rating for Corcept’s RelacorilantApril 23, 2024 | marketbeat.comCorcept Therapeutics (NASDAQ:CORT) Trading Up 7.5%Corcept Therapeutics (NASDAQ:CORT) Trading 7.5% HigherApril 23, 2024 | marketbeat.comCorcept Therapeutics (NASDAQ:CORT) Given Buy Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $38.00 target price on shares of Corcept Therapeutics in a research note on Tuesday.April 22, 2024 | msn.comMid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This QuarterApril 22, 2024 | msn.comCorcept falls after phase 3 results on Cushing's candidate doesn't include some dataApril 22, 2024 | marketbeat.comCorcept Therapeutics (NASDAQ:CORT) Sets New 52-Week Low at $20.84Corcept Therapeutics (NASDAQ:CORT) Hits New 1-Year Low at $20.84April 22, 2024 | marketbeat.comCorcept Therapeutics Sees Unusually Large Options Volume (NASDAQ:CORT)Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) was the recipient of unusually large options trading activity on Monday. Investors purchased 4,326 put options on the company. This represents an increase of approximately 197% compared to the average volume of 1,456 put options.April 22, 2024 | finance.yahoo.comCorcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s SyndromeApril 21, 2024 | marketbeat.com45,200 Shares in Corcept Therapeutics Incorporated (NASDAQ:CORT) Acquired by Louisiana State Employees Retirement SystemLouisiana State Employees Retirement System purchased a new position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 45,200 shares of the biotechnology company's stock, valueApril 19, 2024 | marketbeat.comCerity Partners LLC Has $2.41 Million Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)Cerity Partners LLC decreased its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 85.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 74,067 shares of tApril 18, 2024 | marketbeat.comZacks Research Weighs in on Corcept Therapeutics Incorporated's Q3 2025 Earnings (NASDAQ:CORT)Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Zacks Research upped their Q3 2025 EPS estimates for Corcept Therapeutics in a report issued on Wednesday, April 17th. Zacks Research analyst K. Das now expects that the biotechnology company will post earnings of $0.26 per share forApril 17, 2024 | marketbeat.comCorcept Therapeutics (NASDAQ:CORT) Cut to Buy at StockNews.comStockNews.com downgraded Corcept Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Wednesday.April 16, 2024 | marketbeat.comShort Interest in Corcept Therapeutics Incorporated (NASDAQ:CORT) Increases By 5.5%Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) was the target of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 21,330,000 shares, an increase of 5.5% from the March 15th total of 20,220,000 shares. Approximately 23.9% of the shares of the company are sold short. Based on an average daily volume of 1,420,000 shares, the days-to-cover ratio is presently 15.0 days.April 16, 2024 | marketbeat.comMutual of America Capital Management LLC Purchases 36,255 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)Mutual of America Capital Management LLC raised its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 33.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 144,972 sharesApril 15, 2024 | finance.yahoo.comCorcept Therapeutics Incorporated (CORT)April 15, 2024 | finance.yahoo.comCorcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)April 12, 2024 | stocknews.com3 Promising Biotech Stocks Driving Weekly GainsApril 12, 2024 | msn.comUpcoming Deadline to Share in Corcept Therapeutics Incorporated (CORT) Class Action SettlementApril 9, 2024 | marketbeat.comQ2 2025 EPS Estimates for Corcept Therapeutics Incorporated Raised by Zacks Research (NASDAQ:CORT)Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Equities researchers at Zacks Research boosted their Q2 2025 earnings per share (EPS) estimates for shares of Corcept Therapeutics in a note issued to investors on Monday, April 8th. Zacks Research analyst K. Das now expects that theApril 9, 2024 | insidertrades.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $141,518.00 in StockApril 8, 2024 | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Insider Joseph Douglas Lyon Sells 5,443 SharesCorcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) insider Joseph Douglas Lyon sold 5,443 shares of the company's stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $26.00, for a total value of $141,518.00. Following the completion of the sale, the insider now owns 7,314 shares in the company, valued at $190,164. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Get Corcept Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter. Email Address Global crypto currency reset (41 major banks signed up) (Ad)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. CORT Media Mentions By Week CORT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CORT News Sentiment▼0.790.42▲Average Medical News Sentiment CORT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CORT Articles This Week▼165▲CORT Articles Average Week Get Corcept Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Supernus Pharmaceuticals News Today Taro Pharmaceutical Industries News Today Xencor News Today Axsome Therapeutics News Today Pacira BioSciences News Today Perrigo News Today OPKO Health News Today ADC Therapeutics News Today Atea Pharmaceuticals News Today Jazz Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CORT) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlaceBiden Nomination CANCELED?The Freeport SocietyUrgent Nvidia WarningAltimetryShocking: One AI startup's revenue could surge 4,735%Manward Press"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersDems have chosen Biden replacement?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.